Insulin R Molekülinformation
Molecule Name
Insulin receptor
Molekülalias
INSR,Insulin receptor,IR,CD220
Drug Development Progress
Anzahl der klinischen Arzneimittel96
Anzahl der inverkehr gebrachten Arzneimittel99
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
EC:2.7.10.1，EC 2.7.10，INSR，IR，Insulin receptor，CD220 Antigen，EC 2.7.10.1，CD220，HHF5，Receptor， Insulin
Molekülhintergrund
Insulin receptor (INSR) is also known as CD antigen CD220, which can be cleaved into the following 2 chains: Insulin receptor subunit alpha and Insulin receptor subunit beta. INSR is a tetramer of 2 alpha and 2 beta chains linked by disulfide bonds. The alpha chains carry the insulin-binding regions, while the beta chains carry the kinase domain. Forms a hybrid receptor with IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short of INSR has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, INSR binds IGF1.
Insulin R Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Recombinant human insulin biosimilar (Rechon Life Sciences) | Phase 3 Clinical | Rechon Life Science Ab | Diabetes Mellitus, Type 1 | Details | |
| Recombinant human insulin (Nutrinia) | NTRA-9620 | Phase 3 Clinical | Nutrinia Inc | Diabetes Mellitus, Type 2 | Details |
| Ersodetug | XPA.15.247; XOMA-358; XOMA-247; RZ358; RZ-358 | Phase 3 Clinical | Xoma Corp | Congenital Hyperinsulinism; Hyperinsulinism; Hypoglycemia | Details |
| Insulin mouth rinse (EastGate Biotech) | Phase 3 Clinical | Eastgate Biotech, Genome Pharmaceuticals | Alzheimer Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | |
| Long-acting basal insulin analogue | LAI-287; NN-1436; NN-1956; OI-287GT; 148-0287-A; Insulin-287; NNC0148-0287 C; NNC-0148-0000-0287; Long-acting-insulin-287; Long-acting basal insulin analogue | Phase 3 Clinical | Novo Nordisk A/S | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Ultra fast-acting insulin (Adocia) | THDB-0206; THDB0206; BC-106-Insulin-Lispro; BC-222-Insulin-Lispro | Phase 3 Clinical | Adocia | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin glargine biosimilar (Geropharm) | Phase 3 Clinical | Geropharm | Diabetes Mellitus; Diabetes Mellitus, Type 1 | Details | |
| Insulin biosimilar (Valin Technologies) | Van-101 | Phase 3 Clinical | Valin Technologies | Diabetes Mellitus | Details |
| Insulin glargine (BioGenomics) | Phase 3 Clinical | Biogenomics | Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec/Insulin aspart（Hangzhou Zhongmei Huadong） | HDM-1701; HDM1701 | Phase 3 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| GP-40321 | GP-40321 | Phase 3 Clinical | Geropharm | Diabetes Mellitus; Diabetes Mellitus, Type 1 | Details |
| Insulin degludec/Insulin aspart (Chongqing Chenan Biopharma) | Phase 3 Clinical | Chongqing Chenan Biopharmaceutical Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec/Liraglutide(Lianbang Biotech) | Phase 3 Clinical | Lianbang Biotechnology (Zhuhai Hengqin) Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin aspart biosimilar(Amphastar) | I-004 | Phase 3 Clinical | Amphastar Pharmaceuticals Inc | Details | |
| Insulin degludec biosimilar（Wanbang Pharma） | Phase 3 Clinical | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | ||
| TOTUM•63 | TOTUM-63 | Phase 3 Clinical | Valbiotis | Diabetes Mellitus, Type 2 | Details |
| Recombinant human insulin(Elgan) | ELGN-2112; ELGN-GI | Phase 3 Clinical | Elgan Pharma Ltd | Malabsorption Syndromes; Premature Birth; Short Bowel Syndrome | Details |
| Insulin degludec biosimilar (Chia Tai-Tianqing) | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec biosimilar (Jilin Jinsheng) | Phase 3 Clinical | Jilin Jinsheng Pharmaceutical Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec biosimilar (Chenan Biopharmaceutical) | Phase 3 Clinical | Chongqing Chenan Biopharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin aspart biosimilar (Kunpeng) | Phase 3 Clinical | Ningbo Kunpeng Biological Technology Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Long acting insulin analog (Gan & Lee Pharmaceuticals) | GZR4; GZR-4 | Phase 3 Clinical | Gan & Lee Pharmaceuticals | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Protamine Recombinant Human Insulin (Gan & Lee Pharmaceuticals) | Phase 3 Clinical | Gan & Lee Pharmaceuticals | Diabetes Mellitus, Type 2 | Details | |
| Isophane Protamine Recombinant Human Insulin (Jilin Huisheng Biological ) | Phase 3 Clinical | Jilin Huisheng Biopharmaceutical Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Mixed Protamine Zinc Recombinant Insulin Lispro Injection(25R)（Tonghua Dongbao） | Phase 3 Clinical | Tonghua Dongbao Pharmaceutical Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Insulin enteric-coated(Tsinghua University) | Phase 3 Clinical | Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd, Tsinghua University | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | |
| Insulin Aspart (Beijing Sl Pharmaceutical) | Phase 3 Clinical | Beijing Sl Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Recombinant human insulin(30/70) (Zhejiang Hisun Pharmaceutical) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Linsitinib | OSI-906; ASP-7487; OSI-906AA | Phase 3 Clinical | Astellas Pharma Inc, National Cancer Institute | Adrenocortical Carcinoma; Breast Neoplasms; Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carney Complex; Chondrosarcoma; Colorectal Neoplasms; Endocrine System Diseases; Exophthalmos; Eye Diseases; Gastrointestinal Stromal Tumors; Graves Ophthalmopathy; Hashimoto Disease; Head and Neck Neoplasms; Hormone-Resistant Prostate Neoplasms; Lip Neoplasms; Liver Neoplasms; Mouth Neoplasms; Multiple Myeloma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Paraganglioma; Prostatic Neoplasms; Sarcoma, Ewing; Skin Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Thyroid Diseases | Details |
| Recombinant insulin aspart biosimilar (Biogenomics) | Phase 3 Clinical | Biogenomics | Diabetes Mellitus, Type 2 | Details | |
| AKP-11 | AKP-11 | Phase 2 Clinical | Akaal Pharma | Dermatitis, Atopic; Psoriasis | Details |
| Pramlintide/Insulin | ADO-09 | Phase 2 Clinical | Adocia | Diabetes Mellitus, Type 1 | Details |
| Fast-acting human insulin (Adocia) | BioChaperone-222; Hinsbet-U500 | Phase 2 Clinical | Adocia | Alzheimer Disease; Cognitive Dysfunction; Diabetes Mellitus, Type 1; Metabolic Syndrome | Details |
| Injectable HDV-Rapid Acting Insulin (Diasome Pharmaceuticlas) | Phase 2 Clinical | Diasome Pharmaceuticlas Inc | Diabetes Mellitus, Type 1 | Details | |
| GZR-102 | GZR102; GZR-102 | Phase 2 Clinical | Gan&Lee Pharmaceuticals Shandong Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Ultra-long-acting basal insulin(Gan And Lee Pharmaceuticals) | GZR33; GZR-33 | Phase 2 Clinical | Gan & Lee Pharmaceuticals | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| LY-3938577 | LY3938577; LY-3938577 | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| scp776 | scp776 | Phase 2 Clinical | Silver Creek Pharmaceuticals Inc | Ischemic Stroke | Details |
| NT-219 | NT-219; NT219 | Phase 2 Clinical | TyrNovo Ltd | Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| GZR-101 | GZR101 | Phase 2 Clinical | Gan & Lee Pharmaceuticals | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Insulin oral (Diabetology) | DTY-001 | Phase 2 Clinical | Diabetology Ltd | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin detemir biosimilar (Tonghua Dongbao Pharmaceutical) | Phase 1 Clinical | Tonghua Dongbao Biotechnology Co Ltd | Diabetes Mellitus | Details | |
| Dulaglutide/Basal insulin Fc | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
| Basal insulin Fc (Eli Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
| Recombinant insulin lisargine(Hefei Tianmai Biotech) | Phase 1 Clinical | Hefei Tianmai Biotechnology Development Co Ltd | Diabetes Mellitus | Details | |
| AB-101(Rezolute) | AB-101 | Phase 1 Clinical | Rezolute | Diabetes Mellitus, Type 1 | Details |
| Insulin biosimilar (University of Montreal Health Centre) | Phase 1 Clinical | University Of Montreal Health Centre | Glaucoma | Details | |
| vanadium (Medesis) | NP01; NP-01 | Phase 1 Clinical | Medesis Pharma Sa | Diabetes Mellitus, Type 2 | Details |
| Insulin (Coremed) | Phase 1 Clinical | Coremed | Diabetes Mellitus | Details | |
| Insulin lispro/Insulin glargine | THDB-0207 | Phase 1 Clinical | Adocia | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Basal insulin acylated (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
| BioChaperone Pramlintide Insulin | Phase 1 Clinical | Adocia | Diabetes Mellitus, Type 1 | Details | |
| insulin glargine biosimilar (Stelis) | STLI-001 | Phase 1 Clinical | Stelis Biopharma Pvt Ltd | Diabetes Mellitus | Details |
| C19-A3 GNP | Phase 1 Clinical | Cardiff University | Diabetes Mellitus, Type 1 | Details | |
| Insulin glargine biosimilar (Valin Technologies) | Phase 1 Clinical | Valin Technologies | Diabetes Mellitus | Details | |
| Insulin degludec biosimilar (Tonghua Dongbao) | Phase 1 Clinical | Tonghua Dongbao Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin glargine (GeneSys Biologics) | GEN-1501 | Phase 1 Clinical | GeneSys Biologics Pvt Ltd | Diabetes Mellitus | Details |
| PI-U500 | PI-U500 | Phase 1 Clinical | Portal Diabetes Inc | Diabetes Mellitus, Type 1 | Details |
| Glucose sensing insulin receptor agonist II therapeutic (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
| PJ-021 | PJ021; PJ-021 | Phase 1 Clinical | Chongqing Peg-Bio Biopharm Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Isophane Protamine Human Insulin（30R）(Virtu Pharmako ) | Phase 1 Clinical | Virtu Pharmako (Zhejiang) Co Ltd | Diabetes Mellitus | Details | |
| Recombinant lispro insulin75/25(Gan & Lee Pharma) | Phase 1 Clinical | Gan & Lee Pharmaceuticals | Diabetes Mellitus | Details | |
| Insulin glargine biosimilar (Yifan Pharma) | Phase 1 Clinical | Yifan Pharmaceutical (Shanghai) Co Ltd | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | |
| Proinsulin peptide/calcitriol liposomes(Uniquest) | ASITI-201 | Phase 1 Clinical | Uniquest Pty Ltd | Diabetes Mellitus, Type 1 | Details |
| Insulin degludec/Liraglutide( Chia Tai-Tianqing Pharma) | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec biosimilar（Shandong New Time） | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Glucose sensing insulin receptor agonist therapeutic (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus; Obesity | Details | |
| Glucagon/insulin human(Abvance Therapeutics) | ABV-100 | Phase 1 Clinical | Abvance Therapeutics | Hypoglycemia | Details |
| Insulin degludec/Liraglutide(Dongyangguang) | Phase 1 Clinical | Dongguan City Hec Biological Medicine Res And Development Co Ltd, Guangdong Dongyangguang Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec/Liraglutide(Huisheng Biopharmaceutical) | Phase 1 Clinical | Jilin Huisheng Biopharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin human (Columbia University) | Phase 1 Clinical | Columbia University | Hyperinsulinism; Insulin Resistance; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Prediabetic State | Details | |
| Insulin aspart biosimilar（Jiangsu HengRui） | INS-062; INS062 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Diabetes Mellitus | Details |
| Insulin degludec/Liraglutide(Tonghua Dongbao Pharmaceutical) | Phase 1 Clinical | Tonghua Dongbao Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec biosimilar (Nanjing Cellnuo) | Phase 1 Clinical | Nanjing Cellnuo Biopharmaceutical Co Ltd, Nanjing Sinor Biotechnology Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin aspart /Insulin degludec me-better (Hengrui) | HR20014; HR-20014 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Diabetes Mellitus | Details |
| BC Combo U200 | Phase 1 Clinical | Adocia, Tonghua Dongbao Pharmaceutical Co Ltd | Diabetes Mellitus | Details | |
| Insulin degludec biosimilar (Hisun Pharma) | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec/Insulin aspart (United Laboratories) | Phase 1 Clinical | Lianbang Biotechnology (Zhuhai Hengqin) Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin degludec biosimilar（Zhuhai Jibaikang） | Phase 1 Clinical | Zhuhai Jibaikang Biological Tech Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Insulin lispro protamine biosimilar(50R) (Gan & Lee) | Phase 1 Clinical | Gan & Lee Pharmaceuticals | Diabetes Mellitus | Details | |
| Insulin aspart(Chongqing Chenan) | Phase 1 Clinical | Chongqing Chenan Biopharmaceutical Co Ltd | Diabetes Mellitus | Details | |
| Mixed Protamine Zinc Recombinant Insulin Lispro Injection(50R/25R)（Fosun Pharma） | Phase 1 Clinical | Fosun Holdings Ltd | Diabetes Mellitus, Type 2 | Details | |
| HR-011408 | HR011408; HR-011408 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Diabetes Mellitus | Details |
| Insulin degludec（Beijing ShuangLu Pharmaceutical） | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Mixed Protamine Zinc Recombinant Insulin Lispro Injection(50R)（Tonghua Dongbao） | Phase 1 Clinical | Tonghua Dongbao Pharmaceutical Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Human insulin (Ningbo Kunpeng) | Phase 1 Clinical | Ningbo Kunpeng Biological Technology Co Ltd | Diabetes Mellitus | Details | |
| Insulin aspart (Jilin Jinsheng) | Phase 1 Clinical | Jilin Jinsheng Pharmaceutical Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| NNC0363-0845 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1 | Details | |
| Ultra-concentrated rapid acting insulin aspart (Arecor) | AT278; AT-278 | Phase 1 Clinical | Arecor Ltd | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin Aspart 30 (Liaoning Bo'Ao Bio-Pharmaceutical) | Phase 1 Clinical | Liaoning Bo'Ao Bio-Pharmaceutical Co Ltd | Diabetes Mellitus | Details | |
| Recombinant human insulin (Zhejiang Hisun Pharmaceutical) | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| CB-4211 | CB-4211 | Phase 1 Clinical | Cohbar Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Recombinant human insulin (Eastgate Biotech) | EGP-1214 | Clinical | Eastgate Biotech | Diabetes Mellitus, Type 2; Prediabetic State | Details |
| Oral insulin (Purede) | Clinical | Puredel | Diabetes Mellitus | Details | |
| short-acting insulin biosimilar (Regenix Biosciences) | Clinical | Regenix Biosciences Ltd | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | |
| insulin lispro biosimilar (Genova (Changzhou) Biotechnology) | GN-1101-DP; GN-1101 | Clinical | Diabetes Mellitus | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Isophane Protamine Recombinant Human Insulin Injection (Shenzhen Kexing Biotech) | Approved | Shenzhen Kexing Biological Engineering Co Ltd | 苏泌啉恩 | Mainland China | Diabetes Mellitus | Shenzhen Kexing Biological Engineering Co Ltd | 2003-02-24 | Diabetes Mellitus | Details | |
| Insulin glargine biosimilar (Tonghua Dongbao Pharmaceutical) | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | 长舒霖 | Mainland China | Diabetes Mellitus | Tonghua Dongbao Pharmaceutical Co Ltd | 2019-12-06 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Insulin glargine biosimilar (HEC Pharm) | Approved | Yichang Hec Changjiang Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Yichang Hec Changjiang Pharmaceutical Co Ltd | 2021-11-02 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | ||
| Human insulin biosimilar (Square Pharmaceuticals) | Approved | Square Pharmaceuticals Ltd | Ansulin | Bangladesh | Diabetes Mellitus | Square Pharmaceuticals Ltd | 2013-01-01 | Diabetes Mellitus | Details | |
| Recombinant human insulin (United Laboratories International Holdings) | Approved | Zhongshan Branch of Zhuhai United Laboratories Co Ltd | 优思灵, Uslin, 优思灵R | Mainland China | Diabetes Mellitus | Zhongshan Branch of Zhuhai United Laboratories Co Ltd | 2009-11-25 | Diabetes Mellitus | Details | |
| Insulin glargine biosimilar (Getz Pharma) | Approved | Getz Pharma | Basagine | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | |||||
| Recombinant human insulin (Tonghua Dongbao Pharmaceutical) | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | 甘舒霖, 甘舒霖R | Mainland China | Diabetes Mellitus | Tonghua Dongbao Pharmaceutical Co Ltd | 1998-01-01 | Diabetes Mellitus | Details | |
| Insulin aspart | NN-1218; INA-X14; Insulin X14 | Approved | Novo Nordisk A/S | Novolog, NovoRapid, NovoLog FlexPen, NovoMix, Fiasp, 诺和锐, NovoRapid/NovoLog | EU | Diabetes Mellitus | Novo Nordisk A/S | 1999-09-07 | Alzheimer Disease; Atherosclerosis; Cardiovascular Diseases; Cognitive Dysfunction; Coronary Disease; Delirium; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Hypercholesterolemia; Hypertension; Postoperative Cognitive Complications; Vascular Diseases | Details |
| Insulin glargine biosimilar (LG Life Sciences) | Approved | Lg Chemical Ltd | Basugine | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | |||||
| Insulin biosimilar (Wockhardt) | Approved | Wockhardt Ltd | Wosulin Pen Royale, Wosulin, Wosulin®-R, Wosulin Pen | India | Diabetes Mellitus, Type 1 | Wockhardt Ltd | 2003-10-01 | Diabetes Mellitus; Diabetes Mellitus, Type 1 | Details | |
| Insulin detemir | NN-304 | Approved | Novo Nordisk A/S | 诺和平, Levemir | EU | Diabetes Mellitus | Novo Nordisk A/S | 2004-06-01 | Alzheimer Disease; Atherosclerosis; Cardiovascular Diseases; Cognitive Dysfunction; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Hypercholesterolemia; Hypertension | Details |
| Insulin biosimilar (Popular Pharmaceuticals) | Approved | Popular Pharmaceuticals Plc | Insul R | Bangladesh | Diabetes Mellitus | Popular Pharmaceuticals Plc | 2013-01-01 | Diabetes Mellitus | Details | |
| Insulin degludec/Liraglutide | NN-9068 | Approved | Novo Nordisk A/S | Xultophy, iDegLira | EU | Diabetes Mellitus, Type 2 | Novo Nordisk A/S | 2014-09-18 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Imeglimin hydrochloride | PXL-008; EMD-387008 | Approved | Merck KGaA, Darmstadt, Germany | Twymeeg, ツイミーグ | Japan | Diabetes Mellitus, Type 2 | Poxel Sa, Sumitomo Dainippon Pharma Co Ltd | 2021-06-23 | Diabetes Mellitus, Type 2; Heart Diseases; Hepatic Insufficiency | Details |
| Insulin biosimilar (Sedico) | Approved | Sedico | Insulin H bio R | Egypt | Diabetes Mellitus | Sedico | 2013-02-01 | Diabetes Mellitus | Details | |
| Insulin aspart biosimilar (Biocon/Mylan) | MYL-1601D | Approved | Biocon Ltd | KIRSTY | EU | Diabetes Mellitus | Biosimilar Collaborations Ireland Ltd | 2021-02-05 | Diabetes Mellitus | Details |
| Insulin human (rDNA origin, Lilly) | LY-041001; U-500R; S-3300 | Approved | Eli Lilly And Company | Humulin R Pen, Humulin R Kwikpen, Humulin, Humulin R, 优泌淋R | United States | Diabetes Mellitus, Type 2 | Eli Lilly And Company | Alzheimer Disease; Brain Neoplasms; Cognition Disorders; Cognitive Dysfunction; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Intracranial Aneurysm; Neurocognitive Disorders | Details | |
| Insulin glargine biosimilar (Wockhardt) | Approved | Wockhardt Bio Ag | Glaritus, Glaritus Cart, Glaritus DispoPen | India | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus | Wockhardt Ltd | 2013-01-01 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | |
| Insulin aspart biosimilar (Tonghua Dongbao Pharmaceutical) | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Tonghua Dongbao Pharmaceutical Co Ltd | 2021-10-19 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | ||
| Human insulin biosimilar (MJ Biopharm) | Approved | Mj Biopharm Pvt | Biosulin | India | Diabetes Mellitus | Mj Biopharm Pvt | 2005-12-01 | Diabetes Mellitus | Details | |
| Insulin glargine biosimilar(Shandong New Time Pharmaceutical) | Approved | Lunan Pharmaceutical Group Co | Mainland China | Diabetes Mellitus | Shandong New Time Pharmaceutical Co Ltd | 2022-05-10 | Diabetes Mellitus | Details | ||
| Insulin lispro biosimilar (Sanofi) | SAR-342434 | Approved | Sanofi | Admelog | EU | Diabetes Mellitus | Sanofi Winthrop Industrie SA | 2017-07-18 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin biosimilars (Bioton) | Approved | Bioton Sa | Mainland China | Diabetes Mellitus | Bioton Sa | 2013-01-01 | Diabetes Mellitus | Details | ||
| Insulin glargine biosimilar (Biocon) | MYL-1501D | Approved | Biocon Biopharmaceuticals, Fujifilm Corp, Mylan Nv | Semglee, Basalog | India | Diabetes Mellitus | null | 2009-01-01 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin glargine biosimilar (Wanbang Biochemical) | Approved | Mainland China | Diabetes Mellitus | Fosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd | 2022-08-30 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |||
| Recombinant insulin glargine (Gan & Lee) | GL-GLA | Approved | Gan & Lee Pharmaceuticals | 长秀霖, Basalin | Mainland China | Diabetes Mellitus | Gan & Lee Pharmaceuticals | 2005-05-10 | Diabetes Mellitus; Diabetes Mellitus, Type 1 | Details |
| Insulin degludec/Insulin aspart | NN-1045; NN-5401; NN-1250/Insulin aspart | Approved | Novo Nordisk A/S | Ryzodeg, 诺和佳 | Japan | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus | Novo Nordisk A/S | 2012-12-25 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin human (rDNA origin, Novo Nordisk) | NN-729 | Approved | Novo Nordisk A/S | Novolin R, 诺和灵R, Mixtard, Actraphane, Insulatard | United States | Diabetes Mellitus, Type 2 | Novo Nordisk Inc | 1991-06-25 | Alcoholism; Alzheimer Disease; Cognitive Dysfunction; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hyperglycemia; Lymphoma; Parkinson Disease; Pulmonary Disease, Chronic Obstructive; Smoking Cessation; Spinal Cord Injuries | Details |
| Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | EU | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Adenocarcinoma; Brain metastases; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Glioblastoma; Granuloma, Plasma Cell; Hematologic Neoplasms; Hepatic Insufficiency; Liver Dysfunction; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | Details |
| Isophane Protamine Recombinant Human Insulin biosimilar (Popular Pharmaceuticals) | Approved | Popular Pharmaceuticals Plc | Insulin N | Bangladesh | Diabetes Mellitus | Popular Pharmaceuticals Plc | 2013-01-01 | Diabetes Mellitus | Details | |
| Insulin glargine | U-300; Gla-100; Gla-300; Hoe-901; Hoe-71GT; HOE901-U300 | Approved | Sanofi | 来得时, Lantus, Toujeo, Lantus XR, Optisulin | United States | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Sanofi-Aventis U.S. Llc | 2000-04-20 | Atherosclerosis; Cardiovascular Diseases; Coronary Disease; Cystic Fibrosis; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Hypercholesterolemia; Hyperglycemia; Hypertension; Pemphigus; Skin Diseases; Skin Diseases, Vesiculobullous | Details |
| Insulin human (inhalation powder) | SAR-439065 | Approved | MannKind Corp | Afrezza, Afresa, Technosphere Insulin System | United States | Diabetes Mellitus, Type 2 | MannKind Corp | 2014-06-27 | Asthma; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Glucose Intolerance; Glucose Metabolism Disorders; Hyperglycemia; Hypoglycemia; Pregnancy Complications; Pulmonary Disease, Chronic Obstructive | Details |
| Insulin human | HR-1799 | Approved | Sanofi Deutschland | Insulin Human Winthrop | EU | Diabetic Ketoacidosis; Diabetic Coma; Diabetes Mellitus | Sanofi-Aventis Deutschland Gmbh | 1997-02-21 | Diabetes Mellitus; Diabetic Coma; Diabetic Ketoacidosis; Glaucoma | Details |
| Insulin glargine biosimilar (Incepta Pharmaceuticals) | Approved | Incepta Pharmaceuticals Ltd | Bangladesh | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Incepta Pharmaceuticals Ltd | 2012-08-01 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | ||
| Insulin aspart biosimilar (Sanofi) | SAR-341402; SAR-Asp | Approved | Sanofi | MERILOG, Truvelog | EU | Diabetes Mellitus | Sanofi Winthrop Industrie SA | 2020-06-25 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Recombinant lispro insulin biosimilar (Gan & Lee) | Approved | Gan & Lee Pharmaceuticals | Prandilin, 速秀霖 | Mainland China | Diabetes Mellitus | Gan & Lee Pharmaceuticals | 2006-01-19 | Diabetes Mellitus | Details | |
| Rinsulin NPH (Geropharm) | Approved | Geropharm | Rinsulin NPH | Russian Federation | Diabetes Mellitus | Geropharm | 2012-10-01 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Insulin glargine biosimilar (Lilly/Boehringer Ingelheim) | LY-2963016; LY2963016-U-100; LY2963016-U-200 | Approved | Boehringer Ingelheim International Gmbh, Eli Lilly And Company | Basaglar, Abasaglar, Rezvoglar, Abasria | EU | Diabetes Mellitus | Eli Lilly Nederland BV | 2014-09-09 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hyperglycemia; Renal Insufficiency, Chronic | Details |
| Oral insulin (Generex Biotechnology) | Approved | Generex Biotechnology Corp | Oralin, Oralgen, Oral-lyn, Recosulin | Ecuador | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | null | 2005-01-01 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | |
| Insul 30/70 biosimilar (Popular Pharmaceuticals) | Approved | Popular Pharmaceuticals Plc | Insul 30-70 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational | Details | |||||
| Recombinant Human Insulin (Wanbang Pharma) | Approved | Mainland China | Diabetes Mellitus | Fosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd | 2003-08-29 | Diabetes Mellitus | Details | |||
| Insulin degludec | NN-1250; Insulin-454 | Approved | Novo Nordisk A/S | 诺和达, Tresiba | Japan | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus | Novo Nordisk A/S | 2012-09-28 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin glulisine | HMR-1964 | Approved | Sanofi | 艾倍得, Apidra | United States | Diabetes Mellitus | Sanofi-Aventis U.S. Llc | 2004-04-16 | Alzheimer Disease; Cardiovascular Diseases; Cognitive Dysfunction; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Down Syndrome; Heart Failure; Hyperglycemia; Leukemia; Myocardial Infarction; Respiratory Insufficiency | Details |
| Insulin biosimilar (Julphar) | Approved | Julphar (Gulf Pharmaceutical Industries) | Julphar Insulin R | Tunisia | Diabetes Mellitus | Julphar (Gulf Pharmaceutical Industries) | 2013-10-01 | Diabetes Mellitus | Details | |
| Insulin aspart (Biogenomics) | Approved | Biogenomics, USV Pvt Ltd | INSUQUICK | India | Diabetes Mellitus | USV Pvt Ltd, Biogenomics | 2023-11-01 | Diabetes Mellitus | Details | |
| Insulin Aspart 30 biosimilar (Gan & Lee Pharma) | Approved | Gan & Lee Pharmaceuticals | Mainland China | Diabetes Mellitus | Gan & Lee Pharmaceuticals | 2020-12-02 | Diabetes Mellitus | Details | ||
| Insulin Aspart 30 biosimilar (Zhuhai United Laboratories) | Approved | Zhuhai United Laboratories Co Ltd | Mainland China | Diabetes Mellitus | Zhuhai United Laboratories Co Ltd | 2021-07-12 | Diabetes Mellitus | Details | ||
| Insulin lispro protamine(25R) (Lilly ) | Approved | Lilly Suzhou Pharmaceutical Co Ltd | Diabetes Mellitus | Details | ||||||
| Insulin Aspart 50(Tonghua Dongbao Pharmaceutical) | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Tonghua Dongbao Pharmaceutical Co Ltd | 2022-11-08 | Diabetes Mellitus | Details | ||
| Insulin Aspart 30(onghua Dongbao Pharmaceutical) | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Tonghua Dongbao Pharmaceutical Co Ltd | 2022-11-08 | Diabetes Mellitus | Details | ||
| Recombinant insulin aspart biosimilar (Yichang Hec Changjiang Pharmaceutical) | Approved | Yichang Hec Changjiang Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Yichang Hec Changjiang Pharmaceutical Co Ltd | 2022-10-11 | Diabetes Mellitus | Details | ||
| Insulin Aspart 30 | Approved | Novo Nordisk A/S | 诺和锐30 | Mainland China | Diabetes Mellitus | Novo Nordisk A/S | 2009-09-30 | Diabetes Mellitus | Details | |
| Isophane Protamine Human Insulin（30R）(Gan & Lee ) | Approved | Gan & Lee Pharmaceuticals | Mainland China | Diabetes Mellitus | Gan & Lee Pharmaceuticals | 2021-05-19 | Diabetes Mellitus | Details | ||
| Isophane Protamine Human Insulin（50R）(Zhuhai United Laboratories ) | Approved | Zhongshan Branch of Zhuhai United Laboratories Co Ltd | 优思灵USLIN®50R | Mainland China | Diabetes Mellitus | Zhongshan Branch of Zhuhai United Laboratories Co Ltd | 2010-12-31 | Diabetes Mellitus | Details | |
| Insulin lispro protamine biosimilar(50R) (Wanbang Pharma) | Approved | Mainland China | Diabetes Mellitus, Type 2 | Fosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd | 2024-05-21 | Diabetes Mellitus, Type 2 | Details | |||
| Insulin degludec biosimilar（Jilin Huisheng） | Approved | Jilin Huisheng Biopharmaceutical Co Ltd | Mainland China | Diabetes Mellitus, Type 2 | Jilin Huisheng Biopharmaceutical Co Ltd | 2024-08-05 | Diabetes Mellitus, Type 2 | Details | ||
| Insulin human (rDNA) biosimilar (Baxter) | Approved | Baxter International Inc | Inpremzia, Myxredlin | United States | Diabetes Mellitus | Baxter Healthcare Corp | 2019-06-20 | Diabetes Mellitus | Details | |
| Insulin degludec biosimilar (Zhuhai United) | Approved | Zhuhai United Laboratories Co Ltd | Mainland China | Diabetes Mellitus, Type 2 | Zhuhai United Laboratories Co Ltd | 2026-03-03 | Diabetes Mellitus, Type 2 | Details | ||
| Insulin aspart biosimilar (Hisun Pharma) | Approved | Zhejiang Hisun Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Zhejiang Hisun Pharmaceutical Co Ltd | 2021-09-13 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | ||
| Isophane Protamine Human Insulin (30R) (Hec Pharm) | Approved | Hec Pharm Co Ltd | Mainland China | Diabetes Mellitus | Hec Pharm Co Ltd | 2023-09-19 | Diabetes Mellitus | Details | ||
| Insulin Aspart 30 biosimilar (Jilin Huisheng Biological) | Approved | Jilin Huisheng Biopharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Jilin Huisheng Biopharmaceutical Co Ltd | 2023-12-26 | Diabetes Mellitus | Details | ||
| Insulin aspart biosimilar(Jilin Huisheng Biological) | Approved | Jilin Huisheng Biopharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Jilin Huisheng Biopharmaceutical Co Ltd | 2023-12-26 | Diabetes Mellitus | Details | ||
| Isophane Protamine Human Insulin（50R）(Novo Nordisk ) | Approved | Novo Nordisk A/S | 诺和灵50R | Mainland China | Diabetes Mellitus | Novo Nordisk (China)Pharmaceuticals Co Ltd | 2019-11-27 | Diabetes Mellitus | Details | |
| Isophane Protamine Human Insulin（30R）(Novo Nordisk ) | Approved | Novo Nordisk A/S | 诺和灵30R | Mainland China | Diabetes Mellitus | Novo Nordisk A/S | 1999-07-28 | Diabetes Mellitus | Details | |
| Insulin Aspart 50 biosimilar (Jilin Huisheng Biological) | Approved | Jilin Huisheng Biopharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Jilin Huisheng Biopharmaceutical Co Ltd | 2023-12-26 | Diabetes Mellitus | Details | ||
| Insulin biosimilar (Harvest Moon Pharmaceuticals) | Approved | Harvest Moon | Diabetes Mellitus | Details | ||||||
| 30/70 Mixture Recombinant Human Insulin(Tonghua Dongbao Pharmaceutical) | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | 甘舒霖30R | Mainland China | Diabetes Mellitus | Tonghua Dongbao Pharmaceutical Co Ltd | 2002-05-18 | Diabetes Mellitus | Details | |
| Mixed Protamine Human Insulin(Tonghua Dongbao Pharmaceutical) | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | 甘舒霖N | Mainland China | Diabetes Mellitus | Tonghua Dongbao Pharmaceutical Co Ltd | 1999-01-01 | Diabetes Mellitus | Details | |
| 50/50 Mixture Recombinant Human Insulin（Tonghua Dongbao Pharmaceutical） | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | 甘舒霖50R | Mainland China | Diabetes Mellitus | Tonghua Dongbao Pharmaceutical Co Ltd | 2008-02-04 | Diabetes Mellitus | Details | |
| Insulin Aspart 50 | Approved | Novo Nordisk A/S | 诺和锐50 | Mainland China | Diabetes Mellitus | Novo Nordisk A/S | 2012-02-10 | Diabetes Mellitus | Details | |
| Insulin aspart biosimilar (Gan & Lee) | GL-ASP | Approved | Gan & Lee Pharmaceuticals | Rapilin®30, Rapilin30, 锐秀霖30 | Mainland China | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Gan & Lee Pharmaceuticals | 2020-06-05 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Isophane Protamine Human Insulin(30R)(Lilly) | Approved | Eli Lilly And Company | Mainland China | Diabetes Mellitus | Eli Lilly And Company | Diabetes Mellitus | Details | |||
| Insulin lispro protamine biosimilar(25R) (Gan & Lee) | Approved | Gan & Lee Pharmaceuticals | Prandilin25, 速秀霖25 | Mainland China | Diabetes Mellitus | Gan & Lee Pharmaceuticals | 2014-05-09 | Diabetes Mellitus | Details | |
| Insulin icodec/Semaglutide | NN1535; NN-1535 | Approved | Novo Nordisk A/S | Kyinsu, IcoSema, 诺和杰 | EU | Diabetes Mellitus, Type 2 | Novo Nordisk A/S | 2025-11-24 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Insulin lispro | LY-900027; LY-275585; Lys-B28; Pro-B29; LYSPRO; LY-900014 | Approved | Eli Lilly And Company | Humalog, 优泌乐, Eglucent, Liprolog, Lyumjev, Liumjev | EU | Diabetes Mellitus | Eli Lilly Nederland BV | 1996-04-30 | Corneal Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diabetic Neuropathies; Eye Diseases; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Keratoconus; Obesity; Sjogren's Syndrome; Wounds and Injuries; Xerophthalmia | Details |
| Recombinant human insulin (Biocon) | Approved | Biocon Ltd | Insugen | India | Diabetes Mellitus | Biocon Ltd | 2004-11-10 | Diabetes Mellitus | Details | |
| Isophane Protamine Human Insulin（40R）(Tonghua Dongbao) | Approved | Tonghua Dongbao Pharmaceutical Co Ltd | Diabetes Mellitus | Details | ||||||
| Insulin degludec/Insulin aspart（Jilin Huisheng） | NN-1045; NN-5401; NN-1250/Insulin aspart | Approved | Jilin Huisheng Biopharmaceutical Co Ltd | Mainland China | Diabetes Mellitus, Type 2 | Jilin Huisheng Biopharmaceutical Co Ltd | 2024-07-30 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| Insulin glargine biosimilar (Zhuhai United) | Approved | Zhuhai United Laboratories Co Ltd | Mainland China | Diabetes Mellitus | Zhuhai United Laboratories Co Ltd | 2016-12-23 | Diabetes Mellitus | Details | ||
| Isophane Insulin(Polish Society of Diabetology) | Approved | Polish Society of Diabetology | Diabetes Mellitus | Details | ||||||
| Insulin human(Organon France) | Approved | Organon France | EU | Diabetes Mellitus | Organon France | 1999-11-03 | Diabetes Mellitus | Details | ||
| Insulin glargine (Hefei Tianmai) | Approved | Hefei Tianmai Biotechnology Development Co Ltd | Mainland China | Diabetes Mellitus | Hefei Tianmai Biotechnology Development Co Ltd | 2024-06-18 | Diabetes Mellitus | Details | ||
| Isophane Protamine Recombinant Human Insulin(Novo Nordisk) | Approved | Novo Nordisk (China)Pharmaceuticals Co Ltd | 诺和灵N | Mainland China | Diabetes Mellitus | Novo Nordisk (China)Pharmaceuticals Co Ltd | 2016-06-16 | Diabetes Mellitus | Details | |
| Isophane Protamine Recombinant Human Insulin (BIOTON） | Approved | Bioton Sa | Mainland China | Diabetes Mellitus | Bioton Sa | 2013-03-29 | Diabetes Mellitus | Details | ||
| Insulin Glargine biosimilar (Liaoning Bo'Ao Bio-Pharmaceutical) | Approved | Liaoning Bo'Ao Bio-Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Liaoning Bo'Ao Bio-Pharmaceutical Co Ltd | 2023-12-05 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | ||
| Insulin Aspart 30 (Yichang Hec Changjiang Pharmaceutical) | Approved | Yichang Hec Changjiang Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Yichang Hec Changjiang Pharmaceutical Co Ltd | 2022-11-01 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | ||
| Isophane Protamine Recombinant Human Insulin (Hefei Tianmai Biotechnology) | Approved | Hefei Tianmai Biotechnology Development Co Ltd | Mainland China | Diabetes Mellitus | Hefei Tianmai Biotechnology Development Co Ltd | 2019-09-05 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details | ||
| Recombinant human insulin (Hefei Tianmai Biotechnology) | Approved | Hefei Tianmai Biotechnology Development Co Ltd | Mainland China | Diabetes Mellitus | Hefei Tianmai Biotechnology Development Co Ltd | 2018-04-28 | Diabetes Mellitus | Details | ||
| Lixisenatide/Insulin glargine | HOE-901/AVE-0010 | Approved | Sanofi | Soliqua, iGlarLixi, Suliqua | United States | Diabetes Mellitus, Type 2 | Sanofi-Aventis U.S. Llc | 2016-11-21 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin icodec | NNC-0148-0000-0287; NNC0148-0287 C; OI-287GT; 148-0287-A; NN-1436; NN-1956; Insulin-287; LAI-287; Long-acting basal insulin analogue | Approved | Novo Nordisk A/S | AWIQLI, Awiqli, 诺和期 | Canada | Diabetes Mellitus | Novo Nordisk Canada Inc | 2024-03-12 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| Insulin lispro biosimilar (Wanbang Biopharma) | Approved | Mainland China | Diabetes Mellitus | Fosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd | 2022-01-25 | Diabetes Mellitus | Details | |||
| Recombinant human insulin (Shenzhen Kexing Biotech) | Approved | Shenzhen Kexing Biological Engineering Co Ltd | 苏泌啉, Su Bi Lin | Mainland China | Diabetes Mellitus | Shenzhen Kexing Biological Engineering Co Ltd | 2002-06-10 | Diabetes Mellitus | Details | |
| Recombinant insulin (Horizon Pharma/Ibatech) | Approved | Savient Pharmaceuticals Inc | Poland | Diabetes Mellitus, Type 1 | null | 2002-07-01 | Diabetes Mellitus, Type 1 | Details | ||
| Rosinsulin | Approved | Medsintez | Diabetes Mellitus | Details | ||||||
| Isophane Insulin | Approved | 万苏林 | Mainland China | Diabetes Mellitus | Fosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd | 1997-01-01 | Diabetes Mellitus | Details | ||
| Recombinant human insulin (Incepta) | Approved | Incepta Pharmaceuticals Ltd | Maxsulin | Bangladesh | Diabetes Mellitus | Incepta Pharmaceuticals Ltd | 2012-01-01 | Diabetes Mellitus | Details | |
| Recombinant human insulin (SciGen) | Approved | Generex Biotechnology Corp | Recojet | India | Diabetes Mellitus | null | 2004-12-01 | Diabetes Mellitus | Details | |
| Insulin aspart biosimilar (Zhuhai United Laboratories) | Approved | Zhuhai United Laboratories Co Ltd | 联邦优倍灵, Ublin | Mainland China | Diabetes Mellitus | Zhuhai United Laboratories Co Ltd | 2021-07-12 | Diabetes Mellitus | Details | |
| Recombinant human insulin (HEC Pharm) | Approved | Yichang Hec Changjiang Pharmaceutical Co Ltd | Mainland China | Diabetes Mellitus | Yichang Hec Changjiang Pharmaceutical Co Ltd | 2020-06-05 | Diabetes Mellitus | Details |